Objective To explore the
clinical efficacy of
cetuximab combined FOLFOX
chemotherapy on
colon and
colorectal cancer.
Methods Forty
patients with
colon and
colorectal cancer were randomly divided into
observation group and
control group,and 20 cases for each group.
Patients in
control group were treated with
oxaliplatin +
leucovorin +
5-fluorouracil,and in the
observation group were given
cetuximab (the first does was 400 mg/m2 at the first week,then the second week and follow weeks was 250 mg/m2 1
time/week for 6 week) plus the
treatment as
control group.The
clinical efficacy,adverse effect and 1-year
survival in the two groups were recorded.Results The total effective rate and clinical benefit rate in
observation group were 60% (12/20)and 85% (17/20) respectively,which significantly higher than the
control group (30% (6/20) and 65 % (13/ 20),x2 =18.18,10.67,P < 0.05).
Skin rash rate in
observation group was 55% (11/20),which was significantly higher than that of
control group (15% (3/20),x2 =35.16,P <0.05).Half-year
survival rate and 1-year
survival rate of
patients in
observation group were 75% (15/20) and 45% (9/20) respectively,significantly higher than the
control group (50% (10/20) and 25% (5/20),x2 =13.33,8.791,P < 0.05)~ Conclusion
Treatment scheme of
Cetuximab combined FOLFOX
chemotherapy is proved to be an effect of treating advanced
colon and colorectal and be with the low adverse effect.